Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$141K Sell
1,058
-1,340
-56% -$152K ﹤0.01% 1256
2026
Q1
$267K Buy
2,398
+19
+0.8% +$2.25K ﹤0.01% 890
2025
Q4
$321K Buy
2,379
+1,768
+289% +$193K ﹤0.01% 701
2025
Q3
$52K Buy
+611
New +$37.5K ﹤0.01% 1209

Other funds holding ABVX

Hantz Financial Services's ABVX Position: Q2 2026 in Review

Hantz Financial Services reduced its Abivax (ABVX) stake by 56% in Q2 2026, selling an estimated $152K and leaving 1,058 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

Hantz Financial Services first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. The position peaked at $321K in Q4 2025. 275 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Hantz Financial Services held 1,058 shares of Abivax worth $141K as of Q2 2026.
  • Hantz Financial Services sold 1,340 Abivax shares in Q2 2026, an estimated $152K.
  • Abivax made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1256 holding.
  • Hantz Financial Services first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • Hantz Financial Services's Abivax position peaked at $321K in Q4 2025.
  • 275 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.